SeqWright to Handle DNA Screening/Genotyping for Third Wave's HPV Trials

Jan 04, 2007

NEW YORK (GenomeWeb News) — SeqWright today said it will perform all of the sequencing and analysis for a set of clinical trials being conducted by Third Wave Technologies.

Third Wave is developing two in vitro molecular assays and a genotyping test to screen for human papillomavirus, which has been identified as the cause of approximately 70 percent of cervical cancer cases, SeqWright said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Featured White Papers

Automated Rare Disease Diagnostics

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep

28

Featured Webinar

Clinical Utility of Comprehensive and Fast Genomic Interpretation

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.

Main menu